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RAPID COMMUNICATIONS 
Plasma Levels of 8-Methoxypsoralen Determined by High-Pressure 
Liquid Chromatography in Psoriatic Patients Ingesting Drug from Two 
Manufacturers 
Bo LJUNGGREN, MD, D. MARTIN CARTER, MD, PHD, JosEPH ALBERT, MS, AND TED REID, PHD 
Departments of Dermatology and Ophthalmology, Yale University School of M edicine, N ew Haven, Connecticut, U.S.A. 
We have adapted a rapid and sensitive high-pressure 
liquid chromatographic technique (HPLC) to measure 
plasma levels of 8-methoxypsoralen (8-MOP) in 22 pso-
riatic patients receiving photochemotherapy with 8-
MOP and long-wave ultraviolet light (PUV A). In this 
procedure, 1 ml plasma samples containing ammidin as 
an internal standard are extracted with benzene. After 
evaporation under nitrogen the residue is redissolved in 
methylenechloride:acetonitrile, 95:5, and chromato-
graphed using a normal phase HPLC system with a 10 p. 
silica particle column and a UV detector at 254 nm. The 
sensitivity of the method is 10 ng/ml plasma. Plasma 
concentrations of 8-MOP were measured between 2 and 
4 hr after ingestion of therapeutic doses of 8-MOP pro-
vided by 2 manufacturers. Mean 8-MOP plasma levels 
were 27±35 ng/ml plasma 2 hr after ingestion ofthe only 
drug presently available on the U.S. market, 8-MOP 
(Elder). These values were significantly below (p < 0.001) 
those obtained with 8-MOP (Roche) which were 104±79 
ngjml plasma. A number of patients on 8-MOP (Elder) 
did not have detectable levels of 8-MOP 2 hr after inges-
tion. The time course patterns also differed, possibly 
indicating a slower and less complete absorption for 8-
MOP (Elder). Repeated time course studies in the same 
patient were reproducible ~lt~ough th': a?solute cc;mcen-
trations showed some var1atwn. Prehmmary eVIdence· 
indicates that the plasma levels of 8-MOP have therapeu-
tic relevance. 
Photochemotherapy using 8-methoxypsoralen (8-MOP) com-
bined with long-wave ultraviolet light (UV A) is called PUVA 
and has been used increasingly in recen t years in the treatment 
of psoriasis. PUV A treatment of psoriasis is effective [1 ,2], but 
there is concern about long-term risks of its use. In order to 
avoid PUVA overdosage, and, perhaps equally importa nt, un-
d erdosage, one must closely monitor UV doses a nd the amounts 
of available 8-MOP. The former is readily accomplished, but 
reliable and rapid routine methods for the determination of 8-
MOP concentrations in body fluids ha ve not been available. 
Previous workers have attempted to m easure psoralen concen-
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t rations by various m eans including t hin-layer chromatography 
(3,4], gas chromatography [5-7] a nd combinations (8,9]. High-
pressure liquid chromatography (HPLC ) offers advantages over 
other techniques. With HPLC a rapid, s ingle step a nalysis can 
be performed m easuring 8-MOP plasma levels with a few nan-
ograms per mi. Normal [10] a nd reversed phase HPLC systems 
[11] have been used previously . 
We have measured plasm a levels of 8-MOP in psoriatic 
pa tients on PUV A therapy us ing HPLC with a microparticulate 
silica column. The pharmaceutical packaging properties of 8-
MOP determine the resorbtion, the time course pattern a nd th e 
peak blood levels of the drug. Quantitative blood levels with 8-
MOP provided by diffe rent m a nufacturers might be expected 
to vary. One should not expect to be a ble to translate informa-
tion obtained with one preparation directly to another. Fur-
thermore, the interindividual variation in 8-MOP blood levels 
may be great [ 4,11,12] and comparisons between different prep-
amtions should be m ade in the same patient. Variation in 8-
MOP levels on different occasions in the same patient has not 
been studied previously although this factor could" also influence 
the therapeutic effectiveness. 
MATERIALS AND METHODS 
Patients 
22 persons with severe psoriasis who were undergoing PUV A therapy 
were studied after informed consent had been obtained. There were 9 
females and 13 males, ranging in age from 13-72 (mean age was 43 yr ). 
Blood was drawn by venipuncture and collected in heparinized tubes. 
Plasma was separated and kept at -20°C until analyzed for 8-MOP. 
Blood samples were obtained 2 hr after ingestion of the 8-MOP drug 
(dose 0.5 -0.7 mg/kg body weight) at the time of the patient's UV 
treatment. In 11 patients blood was also collected at hourly intervals 
for 4 to 6 hr after administration of the drug. Time course studies were 
repeated from 2 to 4 times in 7 patients. Two preparations of 18- MOP 
were used: Oxsoralen provided by Paul B. Elder Co. , Bryan, Ohio in 10 
mg capsules; and Ro 21-4345 provided by Hoffmann-La Roche, Nutley, 
New J ersey in 10 mg and 40 mg capsules. 
8-MOP Determinations 
Psoralen standards: 8-MOP was obtained from Sigma Chemical 
Company, St. Louis, Missouri, and recrystallized twice from methanol. 
The purity was confirmed spectrophotometrically. Ammidin and 5-
methoxypsoralen were gifts from AB Draco, Lund, Sweden, and 4,5'8 
trimethylpsoralen was obtained from Aldrich Chemical Company, Mil-
waukee, Wisconsin. These agents were used without fur ther purifica-
tion. Structures of these psoralens are shown in Fig l. All standard 
solutions were freshly prepared in a 95:5 mixture of methylenechloride: 
acetoni trile from 0.01% stock solu tions of psoralens in methylene-
chl.roide. All solvents used were analytical reagent grade. 
Extraction: The extraction procedure was a modification of a tech-
nique described by Puglisi, de Silva, and Meyer (10]. To 1 ml samples 
of plasma were added: 200 ng of ammidin as inte rnal standard; and 2.5 
ml of a l M borate buffer (pH 9.0). Samples were extrac ted with 8 ml of 
benzene at room temperature on a reciprocating shaker for 20 min. 
After centrifugation for 15 min at 5°C the organic layer was transferred 
to another centrifuge tube and evaporated at 45°C under a stream of 
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dry nitrogen. Immediately prior to the chromatographic analysis the 
dry residue was redissolved by agitating in 200 111 of the solvent phase (95:5 methylenechloride:acetonitrile). 
All centrifuge tubes used for the extraction procedure were treated 
with a 2% solution of polyethylene glycol in chloroform for 5 min and 
heated in a drying oven at 150°C for 60 min. 
Chromatographic procedure: A high-pressure liquid chromatograph (Varian 4 l00) equipped with a 254 nm UV-detector (LDC, Riviera 
Beach, Florida) was used for the analysis, which was adapted from 
Puglisi, de S ilva, and Meyer (10). The stationary phase was a micro-
particulate silica gel column (Partis il 10, Whatman Inc., Clifton, New 
Jersey) and the mobile phase was a 95:5 mixture of methylenechloride: 
acetonitrile. The system was equipped with a stop-flow injector, and 
the !1ow rate was 2.2 ml / min. A 20 fLI a liquot of the redissolved sample 
was injected in to the chromatograph. 
Calculations: Determinations of the plasma levels were based on 
peak height measurements. A standard curve was prepared by adding 
increasing amounts of 8- MOP (10 to 400 ng(ml) to control plasma 
samples, each containing the same amount of the standard, ammidin (200 ng/ml) , and plotting the 8- MOP/ammidin peak height ratio on a 
diagram (Fig 2). For statis tical analysis Student's t-test was used 
th roughout. 
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F1c I. Chemical s tructures of psoralen, 8-methoxypsoralen, ammi-
din , 5-methoxypsoralen and 4,5'8- trimethylpsoralen. 
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FIG 2. S tandard curve for 8-methoxypsoralen using ammidin as 
internal s tandard. To 1 ml human plasma were added 200 mg ammidin 
and 10 to 400 mg 8-MOP and the psoralens were extracted with benzene 
and measured by HPLC as described in the methods. 
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Frc 3. Chromatogram of exttact from plasma collected 2 hr after 
the patient had ingested 50 mg 8-MOP. 200 ng of ammidin added to 
plasma sample. The point of injection is indicated by the a.r-row. 
/,Ammidin and 1!,8-MOP. The dotted lines show the retent ion times 
of 5- methoxypsoralen (- --)and trimethylpsoralen (-·-·-)which were 
not present in the example shown in this figure . 
RESULTS 
With the present technique, plasma levels of 8-MOP of 10 
ng/ rnl can be measUl'ed . The relationship between the peak 
heights of 8-MOP and ammidin was linear over a wide range of 
8-MOP wncentrations (Fig 2). A chromatogram of a sample of 
patient plasma with ammidin internal standard is shown in Fig 
3. Ammidin is well separated from plasma impurities as well as 
from 8-MOP. In our system the retention times were: ammidin, 
3.2 min; 5-methoxy-psoralen 3.7 min; 8-MOP 4.2 min; and 
trimethylpsoralen 4.5 min. Similar results to those with the 
Varian 4100 HPLC chromatograph have since been obtained 
by us with an Altex 330 system (Altex Scientific Inc., Berkeley, 
California). 
The 2 hr plasma levels in different patients showed great 
variation, ranging from 0 to 268 ng/ ml. The mean plasma level 
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Frc 4. P lasma levels of 8-methoxypsoralen in PUV A patients 2 hr 
after drug ingestion. Horizontal bars indicate means 0 ,8-MOP 
(Roche); •. 8-MOP (Elder). 
after 8-MOP (Roche) was 104 ng/ml (±79 ng/ ml, n = 18) 
compared to 27 ng/ml (±35 ng/ml, n = 16) after 8-MOP (Elder) 
(Fig 4). T his difference is statistically significant (p < 0.001). 
Plasma. levels as a function of t ime also revealed marked 
differences between the 2 drug brands. Patients receiving 8-
MOP (Elder) usually did not reach the highest plasma level 
until 3 to 4 hr after drug ingestion. In contrast, pat ients on 8-
MOP (Roche) showed a peak at 2 to 3 hr, a nd the maximal 
plasma levels were usually highe.r. R~presentative. time cou~·se 
studies in 4 patients are shown m F1g 5. One patient, studied 
twice on each of the 2 drugs demonstrates this difference clearly 
(Fig 5A). When repeated in the same patient on different days, 
t he time course was reproducible, although t he absolute plasma 
concentrations varied somewhat (Fig 5A and D) . The con-
tents of several 10 mg capsules of 8-MOP (Elder) and 8-MOP 
(Roche) were each dissolved in 100 ml chloroform and filtered. 
Aliquots (10 J.Ll) were diluted 1:100 in the solvent phase (95:5 
methylenechloride:acetonitrile) after which 20 J.L l samples were 
subjected to HPLC as described . By this means we confirmed 
that the capsules of each manufacturer did contain 10 mg of 8-
MOP. 
DISCUSSION 
The d escribed HPLC analysis of 8-MOP after benzene ex-
traction from plasma is a rapid and sensitive technique, and the 
detection limit of 8-MOP is comparable to other assays reported 
[5,9-ll]. The use of HPLC eliminates the need for purification 
procedures, which may be necessary when gas chromatography 
is applied [5,9]. A U glassware used for t he extraction a nd 
evaporation procedures was treated with a 2% solution of pol-
yethy lene glycol wh ich prevented uncontro ll ed losses such as 
pso ralen binding to the glass. In our expe ri ence s il a nization of 
glassware as sometimes recommended [8] had an adverse effect. 
The use of an internal standa rd added befo re the extraction 
of the plasma sample is of major importance in order to be able 
to account for variations in extraction efficiency between indi-
vidual samples. As a n in ternal standard we have chosen am-
midin , a nother 8-substituted pso ralen wh ich has a n HPLC 
retention t ime distinctly d ifferent from that for 8-MOP. Tri-
methylpsoralen a nd 5-methoxypso ra len, were also studied but 
were found to be less sui table as standard. 
Extractions were ini t ia lly performed from whole blood, se rum 
a nd plasma. Chromatograms from se rum or plasma were su-
perior because t hey p roduced less chormatographic impurit ies, 
and 8-MOP concentrations in serum were about twice the 
concentrations of those in whole blood. Serum a nd plasma 
levels were a lmost identical (mean 95.3 ng/ ml vs. 96.9 ng/ ml, n 
= 16) . 
T he wide range of 8-MOP concentrations found in our pa-
tients using the same drug (Fig 4) confirms other reports 
[4,11,12]. Many pharamce utical preparations of 8-MOP are in 
use in different count ries and our results show that b lood levels 
a nd time course relationships established for one 8-MOP drug 
brand may not necessarily hold t rue for another. Two hours 
after drug administration has been considered the optimal time 
for UV -A t herapy because of maximal skin photoreactivity at 
t his time [13,14:]. Some workers, however, have reported maxi-
mal blood levels 112 to 1 h r after drug ingestion [12]. We mea-
sured plasma 8-MOP levels following ingestion of drug fro m 2 
diffe rent manufacturers, and we found considerable differences 
between t he 2 preparations in the blood levels at the t ime of 
UV-A t reatment and in t he t ime course relationships. Plasma 
concentrations 2 hr following 8-MOP (Elder) were s ignificantly 
lower t han t hose following 8-MOP (Roche). Some patients on 
8-MOP (Elder) had no detectable plasma levels at the 2 hr 
point (Fig 4). T his is partly due to t he delayed t ime cou rse seen 
with 8-MOP (Elder), many patients showing moderate and 
increasing plasma levels at 3 and 4 hr (Fig 5). ·The maximal 
levels attained during t he 4-hr study were generally lower with 
8-MOP (Elder) , than with 8-MOP (Roche) . Food intake has 
been shown to influence t he p lasma concentrations of 8-MOP 
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F1c 5. Repeated time course studies in 4 PUV A patients receiving 
either 8-MOP (Roche) (0 ) or 8- MOP (Elder) (e). 
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[8]. The patients we studied were accustomed to taking their 
drugs with a light meal to avoid nausea. We did not modify 
their food intake, preferring to keep this factor unchanged 
during our study. 
Repeated t ime course studies in the same patient with the 
same drug showed a reproducible pattern over the 4-hr period 
of study although the absolute 8-MOP concentrations varied 
from one day to a nother. This has not been reported previously. 
In one patient who was studied twice on both drugs this 
consistency of time course patterns as well as t he difference 
between the 2 drugs is clearly demonstrated (Fig 5A ). Interdrug 
varia tions may be explained on the basis of differences in 
pharmaceutical formulation such as capsule and filler compo-
sit ion and perhaps size of 8-MOP crystals. Differences in actual 
8-MOP content between 2 other proprietary drug preparations 
has also been reported [11]. Our preliminary data suggest that 
8-MOP (Elder) and 8-MOP (Roche) do not differ in the amount 
of 8-MOP they contain. 
In addit ion to differences between the drugs, interindividual 
variation also exists in patients receiving the same drug (Fig 4). 
T his can be a t tributed to variations in rate and amount of 
abso rption of 8-MOP from the gastrointestinal tract as well as 
to differences in the metabolic degradation of the drug. 
A correla tion between 8-MOP plasma levels and skin photo-
sensit ivity has not yet been demonstra ted satisfactorily. Such 
a correlation cannot be studied on the basis of isolated 8-MOP 
blood levels at the t ime of phototesting [ 4], because PUV A 
t herapy also depends upon inherent individual skin photosen-
s it ivity . T he 8-MOP concentration and the skin sensitivity in 
combination should determine the amount of UV A energy 
required to evoke a phototoxic skin reaction in a given individ-
ua l. T his relationship should thus be studied by comparing 
simultaneous 8-MOP blood levels and skin phototests over a 
t ime period in the same patient. Such studies are now in 
progress in our department. It seems likely, however, that the 
bioactivity· of 8-MOP correla tes with blood levels. Several of 
our relatively unresponsive psoria tic patients promptly im-
proved on P UV A therapy when irradiation t ime was changed 
from 2 to 3 hr after ingestion of drug in order to match the time 
of peak blood levels of 8-MOP (Elder) . 
8-MOP (Elder) is the only 8-MOP preparation commercially 
availa ble in the U.S . today and these findings may thus have 
important consequences for the timing and dosage of PUV A 
therapy. Our results emphasize the importance of closely mon-
itoring each of the components of PUV A therapy. Care should 
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be taken to avoid undertreatment of patients receiving 8-MOP 
(Elder1. 
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